Soo Aleman

List of Publications by Citations

77 papers	4,696 citations	22 h-index	68 g-index
83 ext. papers	6,717 ext. citations	9.8 avg, IF	4.75 L-index

#	Paper	IF	Citations
77	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 161-176	18.8	1196
76	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*, **2020** , 183, 158-168.e14	56.2	955
75	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 383-403	18.8	702
74	Natural killer cell immunotypes related to COVID-19 disease severity. *Science Immunology*, **2020**, 5,	28	183
73	A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. *Clinical Infectious Diseases*, **2013**, 57, 230-6	11.6	182
72	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. *Journal of Hepatology*, **2017**, 66, 485-493	13.4	160
71	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 325-336	18.8	153
70	Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. *New England Journal of Medicine*, **2020**, 382, 1018-1028	59.2	96
69	Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. *Aids*, **2002**, 16, 1039-44	3.5	86
68	Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19		85
67	MAIT cell activation and dynamics associated with COVID-19 disease severity. *Science Immunology*, **2020**, 5,	28	74
66	Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.. *Nature Medicine*, **2022**,	50.5	59
65	Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. *Journal of Viral Hepatitis*, **2008**, 15, 538-50	3.4	57
64	Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	54
63	Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. *Annals of Internal Medicine*, **2019**, 171, 318-327	8	51
62	Tissue-resident MAIT cell populations in human oral mucosa exhibit an activated profile and produce IL-17. *European Journal of Immunology*, **2019**, 49, 133-143	6.1	48
61	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. *Clinical Infectious Diseases*, **2019**, 69, 2218-2227	11.6	34

60	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. *EBioMedicine*, **2021**, 74, 103705	8.8	34
59	The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. *Scandinavian Journal of Gastroenterology*, **2015**, 50, 233-44	2.4	32
58	Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C. *Clinical Infectious Diseases*, **2016**, 63, 723-9	11.6	28
57	Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. *Scandinavian Journal of Infectious Diseases*, **2009**, 41, 679-84		26
56	Innate lymphoid cell composition associates with COVID-19 disease severity. *Clinical and Translational Immunology*, **2020**, 9, e1224	6.8	24
55	Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. *Hepatology*, **2020**, 72, 1177-1190	11.2	21
54	TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity. *Journal of Immunology*, **2012**, 189, 4510-9	5.3	19
53	Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels. *AIDS Research and Human Retroviruses*, **1999**, 15, 1249-54	1.6	17
52	SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation. *Clinical and Translational Immunology*, **2021**, 10, e1306	6.8	16
51	Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. *Journal of Infectious Diseases*, **2021**, 224, 407-414	7	14
50	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	14
49	Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. *Infectious Diseases*, **2018**, 50, 569-583	3.1	13
48	Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. *Scandinavian Journal of Infectious Diseases*, **2012**, 44, 502-21		13
47	Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. *Scandinavian Journal of Gastroenterology*, **2008**, 43, 1378-86	2.4	13
46	High plasma levels of soluble fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy. *AIDS Research and Human Retroviruses*, **2000**, 16, 1379-84	1.6	13
45	Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon- production. *Gut*, **2012**, 61, 589-96	19.2	12
44	Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients. *European Journal of Gastroenterology and Hepatology*, **2019**, 31, 506-513	2.2	12
43	Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. *Infectious Diseases*, **2017**, 49, 561-575	3.1	11

42	Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. *Infectious Diseases*, **2016**, 48, 251-261	3.1	11
41	Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 61-68	2.4	11
40	Health check-ups and family screening allow detection of hereditary hemochromatosis with less advanced liver fibrosis and survival comparable with the general population. *Scandinavian Journal of Gastroenterology*, **2011**, 46, 1118-26	2.4	11
39	Management of hepatitis B virus infection, updated Swedish guidelines. *Infectious Diseases*, **2020**, 52, 1-22	3.1	11
38	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.. *The Lancet Gastroenterology and Hepatology*, **2022**, 7, 396-415	18.8	11
37	Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties. *Journal of Virology*, **2017**, 91,	6.6	10
36	Expansion of donor-unrestricted MAIT cells with enhanced cytolytic function suitable for TCR redirection. *JCI Insight*, **2021**, 6,	9.9	10
35	Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. *PLoS ONE*, **2018**, 13, e0190146	3.7	9
34	MAIT cell activation and dynamics associated with COVID-19 disease severity and outcome		9
33	Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection. *Scientific Reports*, **2020**, 10, 2081	4.9	8
32	Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. *Scandinavian Journal of Gastroenterology*, **2019**, 54, 1042-1050	2.4	8
31	Hepatocellular carcinoma in individuals with HBV infection or HBV-HCV co-infection in a low endemic country. *Scandinavian Journal of Gastroenterology*, **2010**, 45, 944-52	2.4	8
30	Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. *Liver International*, **2020**, 40, 1832-1840	7.9	8
29	Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease. *Scandinavian Journal of Gastroenterology*, **2020**, 55, 178-183	2.4	6
28	Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. *BMC Infectious Diseases*, **2019**, 19, 955	4	6
27	IL13Rα2 expression identifies tissue-resident IL-22-producing PLZF innate T cells in the human liver. *European Journal of Immunology*, **2018**, 48, 1329-1335	6.1	5
26	Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients. *Biochemical and Biophysical Research Communications*, **2013**, 433, 31-5	3.4	5
25	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals.. *Med*, **2022**,	31.7	5

24	Kinetics of Chemokine Levels during Anti-HIV Therapy. *Antiviral Therapy*, **1999**, 4, 109-115	1.6	5
23	Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy. *Clinics and Research in Hepatology and Gastroenterology*, **2021**, 45, 101564	2.4	4
22	Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 63-70	4	3
21	Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies. *Cells*, **2020**, 9,	7.9	3
20	Functional attributes of responding T cells in HCV infection: the recent advances in engineering functional antiviral T cells. *Archivum Immunologiae Et Therapiae Experimentalis*, **2014**, 62, 23-30	4	3
19	Probabilistic approaches for classifying highly variable anti-SARS-CoV-2 antibody responses		3
18	Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus. *Gut*, **2020**, 69, 2203-2213	19.2	2
17	Minor nef gene alterations after human HIV-DNA immunisation. *Aids*, **2004**, 18, 817-9	3.5	2
16	High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?. *Aids*, **2022**, 36, 479-481	3.5	2
15	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.. *Molecular Medicine*, **2022**, 28, 20	6.2	2
14	COVID-19 specific metabolic imprint yields insights into multi organ-system perturbations. *European Journal of Immunology*, **2021**,	6.1	1
13	Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct-acting antivirals. *GastroHep*, **2021**, 3, 185-195	1	1
12	Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19. *Liver International*, **2021**, 41, 2024-2031	7.9	1
11	Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. *Journal of Viral Hepatitis*, **2021**, 28, 1431-1442	3.4	1
10	Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. *JHEP Reports*, **2021**, 3, 100318	10.3	1
9	Probabilistic classification of anti-SARS-CoV-2 antibody responses improves seroprevalence estimates.. *Clinical and Translational Immunology*, **2022**, 11, e1379	6.8	1
8	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.. *JHEP Reports*, **2022**, 4, 100462	10.3	1
7	Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant.. *Journal of Clinical Immunology*, **2022**, 1	5.7	1

6	High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder. *Scandinavian Journal of Gastroenterology*, **2020**, 55, 574-580	2.4	0
5	Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron. *Nature Medicine*,	50.5	0
4	Mortality among amphetamine users with hepatitis C virus infection: A nationwide study. *PLoS ONE* , **2021**, 16, e0253710	3.7	0
3	Elevated CD21 B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency.. *Journal of Clinical Immunology*, **2022**, 1	5.7	0
2	MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine.. *Molecular Medicine*, **2022**, 28, 54	6.2	0
1	REPLY. *Hepatology*, **2021**, 74, 1127-1128	11.2	